{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:46:01Z","timestamp":1769121961444,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jviromet.2018.10.003","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T14:07:54Z","timestamp":1540476474000},"page":"54-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development and pre-validation of a quantitative multi-dose serological assay for potency testing of inactivated rabies vaccines for human use"],"prefix":"10.1016","volume":"263","author":[{"given":"Wildeberg C\u00e1l","family":"Moreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica F.S.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalia S.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio Eug\u00eanio Castro Cardoso","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlamir Corr\u00eaa de","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2018.10.003_bib0005","series-title":"Zoonosis y enfermedades transmissibles comunes al hombre y a a los animales","first-page":"351","article-title":"Rabia","author":"Acha","year":"2003"},{"issue":"3","key":"10.1016\/j.jviromet.2018.10.003_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1590\/S0036-46652002000300007","article-title":"Lima Filho JHC, Zanetti CR. Calculating rabies virus neutralizing antibodies titres by flow cytometry","volume":"44","author":"Bordignon","year":"2002","journal-title":"Rev. Inst. Med. Trop. S Paulo"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0015","first-page":"1366","volume":"vol. 2","author":"Brasil","year":"2010"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0020","first-page":"1297","volume":"vol. 2","author":"Brasil","year":"2010"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biologicals.2017.02.002","article-title":"G-protein based ELISA as a potency test for rabies vaccines","volume":"46","author":"Chabaud-Riou","year":"2017","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.jviromet.2018.10.003_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1590\/S1678-91992007000100002","article-title":"Rabies review: immunopathology, clinical aspects and treatment","volume":"13","author":"Consales","year":"2007","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0035","series-title":"The European Pharmacopoeia. Rabies Vaccine (inactivated) for Veterinary Use","author":"Council of Europe","year":"2013"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0040","series-title":"The European Pharmacopoeia. Rabies Vaccine for Human Use Prepared in Cell Cultures","first-page":"3952","author":"Council of Europe","year":"2015"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0045","series-title":"Application of the 3rs and the Consistency Approach for Improved Vaccine Quality Control","author":"European Partnership for Alternative Approaches (EPAA)","year":"2012"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0050","series-title":"Probit Analysis","author":"Finney","year":"1971"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1996.0012","article-title":"Use of ELISA for in vitro potency test of rabies vaccines for animal use","volume":"24","author":"Gamoh","year":"1996","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0060","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.vaccine.2013.10.019","article-title":"A relevant in vitro ELISA test in alternative to the in vivo NIH test forhuman rabies vaccine batch release","volume":"31","author":"Gibert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0065","series-title":"The Laboratory Mouse","author":"Hedrich","year":"2004"},{"issue":"6","key":"10.1016\/j.jviromet.2018.10.003_bib0070","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0887-2333(95)00088-7","article-title":"Development, validation and acceptance of alternative methods in the quality control of vaccines: a case report","volume":"9","author":"Hendriksen","year":"1995","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/1045-1056(91)90020-K","article-title":"The use of the in vitro toxin binding inhibition (ToBI) test for the estimation of the potency of tetanus toxoid","volume":"19","author":"Hendriksen","year":"1991","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0080","series-title":"International Committee on Taxonomy of Viruses - ICTV","author":"ICTV 9th Report","year":"2011"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0085","series-title":"ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1)","first-page":"17","author":"International Conference on Harmonisation of Technical Requirements for Registration of pharmaceuticals for Human Use (ICH)","year":"2005"},{"issue":"7","key":"10.1016\/j.jviromet.2018.10.003_bib0090","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1128\/AAC.06179-11","article-title":"Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples","volume":"56","author":"Kostense","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biologicals.2009.01.001","article-title":"The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines","volume":"37","author":"Kr\u00e4mer","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0100","first-page":"37","article-title":"Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use","volume":"2","author":"Kr\u00e4mer","year":"2010","journal-title":"Pharmeur. Biol. Sci. Notes"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biologicals.2013.08.003","article-title":"A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use","volume":"41","author":"Kr\u00e4mer","year":"2013","journal-title":"Biol"},{"issue":"7288","key":"10.1016\/j.jviromet.2018.10.003_bib0110","first-page":"1","article-title":"A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency","volume":"7","author":"Lin","year":"2017","journal-title":"Sci. Rep."},{"issue":"RR-3","key":"10.1016\/j.jviromet.2018.10.003_bib0115","first-page":"1","article-title":"Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on immunization practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0120","first-page":"65","article-title":"EDQM\u2019s 3R activities in the field of quality control of vaccines","volume":"1\/12","author":"Milne","year":"2012","journal-title":"ALTEX Proc."},{"issue":"April-June 2","key":"10.1016\/j.jviromet.2018.10.003_bib0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1590\/1677-5449.041117","article-title":"Assessing normality of data in clinical and experimental trials","volume":"16","author":"Miot","year":"2017","journal-title":"J Vasc. Bras."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0130","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.vaccine.2016.12.039","article-title":"Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA \u2013 results of an international collaborative study","volume":"35","author":"Morgeaux","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2008.09.010","article-title":"Validation of a virus neutralization potency test in BHK-21 cells for rabies immunoglobulins in a two-center study","volume":"54","author":"Moura","year":"2008","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0140","series-title":"N\u00ba 34. Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment","author":"Organization for Economic Co-Operation and Development (OECD)","year":"2005"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/1045-1056(90)90037-Z","article-title":"In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing antiglycoprotein monoclonal antibody","volume":"18","author":"Perrin","year":"1990","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0150","series-title":"Vaccine Analysis: Strategies, Principles and Control","first-page":"521","article-title":"Vaccine potency assays","author":"Ranhein","year":"2015"},{"issue":"6","key":"10.1016\/j.jviromet.2018.10.003_bib0155","first-page":"33","article-title":"The roles of bioactivity assays in lot release and stability testing","volume":"8","author":"Rieder","year":"2010","journal-title":"Bioprocess. Int."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0160","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(02)00287-6","article-title":"Rabies re-examined","volume":"2","author":"Rupprecht","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.biologicals.2014.04.001","article-title":"Replacing the NIH test for rabies vaccine potency testing: a synopsis of drivers and barriers","volume":"42","author":"Schiffelers","year":"2014","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.jviromet.2018.10.003_bib0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12665\/J113.Schrock","article-title":"Cell-ased potency assays: expectations and realities","volume":"11","author":"Schrock","year":"2012","journal-title":"BioProcess. J."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0175","first-page":"19","article-title":"A step forward in the quality control testing of inactivated rabies vaccines - extensive evaluation of european vaccines by using alternative methods to the in vivo potency tests","volume":"43","author":"Servat","year":"2015","journal-title":"ATLA"},{"issue":"32","key":"10.1016\/j.jviromet.2018.10.003_bib0180","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1016\/j.vaccine.2015.06.091","article-title":"A versatile in vitro ELISA test for quantification and quality testing of infectious, inactivated and formulated rabies virus used in veterinary monovalent or combination vaccine","volume":"33","author":"Sigoillot-Claude","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0185","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biologicals.2012.07.005","article-title":"Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward","volume":"40","author":"Stokes","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0190","unstructured":"The United States Pharmacopoeia (USP). Development and Design of Biological Assays <1032>. USP 35 \u2013 NF 30:162, 2017. [Accessed in 2017 May 15]. Available from: http:\/\/www.usp.org\/sites\/default\/fies\/usp_pdf\/EN\/2010-03-25_1032_PF36(4)_w_line_numbers.pdf."},{"issue":"2","key":"10.1016\/j.jviromet.2018.10.003_bib0195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/biol.2000.0247","article-title":"The Pertussis Serological Potency test. Collaborative study to evaluate replacement of the mouse protection test","volume":"28","author":"van der Ark","year":"2000","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0200","series-title":"The Natural History of Rabies","first-page":"571","article-title":"Human vaccination against rabies","author":"Vodopija","year":"1991"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0205","series-title":"Laboratory Techniques in Rabies","first-page":"360","article-title":"The NIH test for potency","author":"Wilbur","year":"1996"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0210","unstructured":"Winsnes R, Sesardic D, Daas A, Behr-Gross M-E. Collaborative Study for the Validation of Serological Methods for Potency Testing of Diphtheria Toxoid Vaccines Part 1. Pharmeuropa Bio 2003\u20132; 35\u201368."},{"key":"10.1016\/j.jviromet.2018.10.003_bib0215","series-title":"WHO Expert Consultation on Rabies, First Report","author":"World Health Organisation","year":"2005"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0220","series-title":"Recommendations for the Preparation, Characterization and Establishment of International and Other Biological Reference Standards","author":"World Health Organisation","year":"2006"},{"key":"10.1016\/j.jviromet.2018.10.003_bib0225","series-title":"Recommendations for Inactivated Rabies Vaccine for Human Use Produced in Cell Substrates and Embryonated Eggs","first-page":"109","author":"World Health Organization","year":"2007"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093418303276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093418303276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T03:42:02Z","timestamp":1544067722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093418303276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":45,"alternative-id":["S0166093418303276"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2018.10.003","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and pre-validation of a quantitative multi-dose serological assay for potency testing of inactivated rabies vaccines for human use","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}